Previous Page  13 / 15 Next Page
Information
Show Menu
Previous Page 13 / 15 Next Page
Page Background

Volume 2, Issue 3 2017

Journal of Medical Oncology and Therapeutics

Dermatologists & Melanoma 2017

August 31-September 01, 2017

Page 83

&

2

nd

Euro-Global Congress on

August 31-September 01, 2017 London, UK

12

th

Global Dermatologists Congress

Melanoma and Skin Diseases

Just see me: Pigmentation solutions for higher fitzpatrick skin types

Pamela R Springer

Global Skin Solutions LLC, USA

H

yperpigmentation generally presents as a hypermelanosis on the face of predominantly females. These dark patches and

spots of hyperpigmentation can be a disfiguring cosmetic and emotional problem. Pigmentary disorders rank among the

top five most common skin complaints in several ethnic groups, including blacks, Arabs, and South Asians.The male population

is affected as well. The exact cause is unknown but thought to be strongly influenced by exposure to UV radiation, pregnancy,

hormonal therapies, phototoxic drugs, anti-seizure medication and genetic predisposition. The skin of colour population is

more prone to encounter this challenging disorder. Reviewing the science related to the complex process of melanogenesis

in skin of colour will determine the different types of pigmentary lesions. It is important to reveal the trigger mechanisms

including the cultural practices and beliefs. Many times these can impact the outcome of a treatment. Published studies have

summarized the best practices based on current research findings. The clinical presentation of epidermal hypermelanosis, with

the use of a woods lamp, shows the pigment is intensified. In the superficial dermis and mid dermis the pigment is subdued. If

a mixed component, both epidermal and dermal types, in the woods lamp, the light is absorbed by increased melanin. In the

hierarchy of therapies, the treating physician must consider the pigment imperfections within the realm of benefits and risks

associated with each treatment.

info@pamelaspringer.com

J Med Oncl Ther 2017, 2:3